An Active Surveillance, Post Authorization Safety Study (PASS) to Investigate Relevant Safety Outcomes among Patients Treated with Flixabi for Rheumatoid Arthritis (RA) within the German Registry Rheumatoide Arthritis: Beobachtung der Biologika-Therapie (RABBIT)

06/08/2026
06/08/2026
EU PAS number:
EUPAS1000001076
Study
Finalised
Documents
Study protocol
Study results
Study report
Abstract of study report
English (1.21 MB - PDF) View document
Other information